Skip to main navigation

Prime Medicine Logo

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Sec filings
IR Resources

Press Releases

Year

July 23, 2026

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

July 8, 2026

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

June 22, 2026

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

June 18, 2026

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

June 3, 2026

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

May 28, 2026

Prime Medicine to Present at Jefferies Global Healthcare Conference

May 7, 2026

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

April 16, 2026

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

March 3, 2026

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

February 25, 2026

Prime Medicine to Participate in Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Print Page

Email Alerts

RSS Feeds

Contact IR

prime_

Site - Footer Bottom

Contact Us
Privacy Policy
Terms of Use

© 2021-2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE and the Prime Medicine logos are trademarks of Prime Medicine, Inc.